AR040129A1 - Uso de los esteres de etonogestrel - Google Patents
Uso de los esteres de etonogestrelInfo
- Publication number
- AR040129A1 AR040129A1 ARP030101858A ARP030101858A AR040129A1 AR 040129 A1 AR040129 A1 AR 040129A1 AR P030101858 A ARP030101858 A AR P030101858A AR P030101858 A ARP030101858 A AR P030101858A AR 040129 A1 AR040129 A1 AR 040129A1
- Authority
- AR
- Argentina
- Prior art keywords
- contraceptive
- disorder
- long
- chain length
- effective amount
- Prior art date
Links
- GCKFUYQCUCGESZ-BPIQYHPVSA-N etonogestrel Chemical class O=C1CC[C@@H]2[C@H]3C(=C)C[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 GCKFUYQCUCGESZ-BPIQYHPVSA-N 0.000 title 1
- 239000003433 contraceptive agent Substances 0.000 abstract 3
- 230000002254 contraceptive effect Effects 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 208000035475 disorder Diseases 0.000 abstract 3
- 229960002941 etonogestrel Drugs 0.000 abstract 2
- -1 etonogestrel ester Chemical class 0.000 abstract 2
- 208000005171 Dysmenorrhea Diseases 0.000 abstract 1
- 206010013935 Dysmenorrhoea Diseases 0.000 abstract 1
- 201000009273 Endometriosis Diseases 0.000 abstract 1
- 206010027295 Menometrorrhagia Diseases 0.000 abstract 1
- 206010036618 Premenstrual syndrome Diseases 0.000 abstract 1
- 208000007106 menorrhagia Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Gynecology & Obstetrics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Pregnancy & Childbirth (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP02077118 | 2002-05-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR040129A1 true AR040129A1 (es) | 2005-03-16 |
Family
ID=29595013
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP030101858A AR040129A1 (es) | 2002-05-30 | 2003-05-28 | Uso de los esteres de etonogestrel |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US20050222114A1 (https=) |
| EP (1) | EP1513588B1 (https=) |
| JP (1) | JP2005532336A (https=) |
| KR (1) | KR20050005507A (https=) |
| CN (1) | CN1655848A (https=) |
| AR (1) | AR040129A1 (https=) |
| AT (1) | ATE394140T1 (https=) |
| AU (1) | AU2003246740B2 (https=) |
| BR (1) | BR0311248A (https=) |
| CA (1) | CA2487293A1 (https=) |
| DE (1) | DE60320786D1 (https=) |
| ES (1) | ES2305498T3 (https=) |
| HR (1) | HRP20041127A2 (https=) |
| IL (1) | IL165125A0 (https=) |
| IS (1) | IS7537A (https=) |
| MX (1) | MXPA04011798A (https=) |
| NO (1) | NO20044903L (https=) |
| NZ (1) | NZ536618A (https=) |
| PE (1) | PE20040042A1 (https=) |
| PL (1) | PL373295A1 (https=) |
| RS (1) | RS101004A (https=) |
| RU (1) | RU2322986C2 (https=) |
| TW (1) | TW200400041A (https=) |
| UA (1) | UA80703C2 (https=) |
| WO (1) | WO2003101374A2 (https=) |
| ZA (1) | ZA200409498B (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200403065A (en) * | 2002-05-30 | 2004-03-01 | Akzo Nobel Nv | New etonogestrel esters |
| US20130123523A1 (en) * | 2011-11-10 | 2013-05-16 | Klaus Nickisch | Methods for the preparation of etonogestrel and desogestrel |
| DE102012211511A1 (de) * | 2012-07-03 | 2014-01-09 | Siemens Aktiengesellschaft | Bestimmung der Eignung einer Ressource |
| US10624903B2 (en) * | 2017-10-19 | 2020-04-21 | Evestra, Inc. | Longer-acting progestin prodrug contraceptives |
| CN111057120B (zh) * | 2019-12-27 | 2021-04-27 | 苏州翔实医药发展有限公司 | 一种依托孕烯衍生物a及其制备方法和用途 |
| US20230227492A1 (en) * | 2020-06-11 | 2023-07-20 | The Usa As Represented By The Secretary, Department Of Health And Human Services | Monomeric and oligomeric compound embodiments as contraceptives and therapies and methods of making and using the same |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4227989A1 (de) * | 1992-08-21 | 1994-06-09 | Schering Ag | Mittel zur transdermalen Applikation enthaltend 3-Keto-desogestrel |
| DE4240806A1 (de) * | 1992-12-01 | 1994-06-09 | Schering Ag | Mittel zur transdermalen Applikation enthaltend 14alpha,17alpha-Ethanoestra-1,3,5(10)-trien-3,17beta-diol |
| JPH07101884A (ja) * | 1993-10-01 | 1995-04-18 | Sanei Gen F F I Inc | 水溶性ヘミセルロースを含有する製剤 |
| HUT75159A (en) * | 1993-12-27 | 1997-04-28 | Akzo Nobel Nv | Percutaneously absorbable preparation, containing 3-ketodesogestrel and 17 beta-estradiol |
| EP0848620A1 (de) * | 1995-07-17 | 1998-06-24 | Schering Aktiengesellschaft | Mittel zur transdermalen applikation enthaltend ester des 3-ketodegestrel |
| WO1999067270A1 (en) * | 1998-06-19 | 1999-12-29 | Akzo Nobel N.V. | Cycloalkyl-carboxylic acid esters of 7.alpha.methyl-estr-4-en-3-one 17.beta.-ol (19-nor 7.alpha.-methyltestosterone) |
| NZ508299A (en) * | 1998-06-19 | 2003-04-29 | Akzo Nobel Nv | Testosterone derivative |
| US6180682B1 (en) * | 1999-01-26 | 2001-01-30 | Virgil A. Place | Buccal drug delivery system for use in male contraception |
| TW200403065A (en) * | 2002-05-30 | 2004-03-01 | Akzo Nobel Nv | New etonogestrel esters |
-
2003
- 2003-05-19 TW TW092113492A patent/TW200400041A/zh unknown
- 2003-05-22 BR BR0311248-9A patent/BR0311248A/pt not_active IP Right Cessation
- 2003-05-22 RU RU2004138809/15A patent/RU2322986C2/ru active
- 2003-05-22 NZ NZ536618A patent/NZ536618A/en unknown
- 2003-05-22 EP EP03755980A patent/EP1513588B1/en not_active Expired - Lifetime
- 2003-05-22 AU AU2003246740A patent/AU2003246740B2/en not_active Ceased
- 2003-05-22 US US10/517,362 patent/US20050222114A1/en not_active Abandoned
- 2003-05-22 PL PL03373295A patent/PL373295A1/xx not_active Application Discontinuation
- 2003-05-22 CN CNA038123657A patent/CN1655848A/zh active Pending
- 2003-05-22 CA CA002487293A patent/CA2487293A1/en not_active Abandoned
- 2003-05-22 MX MXPA04011798A patent/MXPA04011798A/es unknown
- 2003-05-22 DE DE60320786T patent/DE60320786D1/de not_active Expired - Fee Related
- 2003-05-22 AT AT03755980T patent/ATE394140T1/de not_active IP Right Cessation
- 2003-05-22 UA UA20041109285A patent/UA80703C2/uk unknown
- 2003-05-22 KR KR10-2004-7019327A patent/KR20050005507A/ko not_active Withdrawn
- 2003-05-22 JP JP2004508732A patent/JP2005532336A/ja not_active Withdrawn
- 2003-05-22 ES ES03755980T patent/ES2305498T3/es not_active Expired - Lifetime
- 2003-05-22 RS YU101004A patent/RS101004A/sr unknown
- 2003-05-22 WO PCT/EP2003/050188 patent/WO2003101374A2/en not_active Ceased
- 2003-05-22 HR HR20041127A patent/HRP20041127A2/hr not_active Application Discontinuation
- 2003-05-26 PE PE2003000508A patent/PE20040042A1/es not_active Application Discontinuation
- 2003-05-28 AR ARP030101858A patent/AR040129A1/es unknown
-
2004
- 2004-11-09 IL IL16512504A patent/IL165125A0/xx unknown
- 2004-11-10 NO NO20044903A patent/NO20044903L/no not_active Application Discontinuation
- 2004-11-18 IS IS7537A patent/IS7537A/is unknown
- 2004-11-24 ZA ZA200409498A patent/ZA200409498B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES2305498T3 (es) | 2008-11-01 |
| PE20040042A1 (es) | 2004-01-31 |
| WO2003101374A3 (en) | 2004-02-26 |
| RU2322986C2 (ru) | 2008-04-27 |
| IL165125A0 (en) | 2005-12-18 |
| AU2003246740B2 (en) | 2009-01-08 |
| EP1513588B1 (en) | 2008-05-07 |
| RU2004138809A (ru) | 2005-06-10 |
| AU2003246740A1 (en) | 2003-12-19 |
| DE60320786D1 (de) | 2008-06-19 |
| HK1072568A1 (en) | 2005-09-02 |
| CN1655848A (zh) | 2005-08-17 |
| PL373295A1 (en) | 2005-08-22 |
| US20050222114A1 (en) | 2005-10-06 |
| IS7537A (is) | 2004-11-18 |
| BR0311248A (pt) | 2005-03-15 |
| EP1513588A2 (en) | 2005-03-16 |
| NO20044903L (no) | 2005-02-25 |
| NZ536618A (en) | 2007-06-29 |
| RS101004A (sr) | 2006-10-27 |
| CA2487293A1 (en) | 2003-12-11 |
| UA80703C2 (en) | 2007-10-25 |
| JP2005532336A (ja) | 2005-10-27 |
| ZA200409498B (en) | 2006-05-31 |
| TW200400041A (en) | 2004-01-01 |
| MXPA04011798A (es) | 2005-03-31 |
| KR20050005507A (ko) | 2005-01-13 |
| HRP20041127A2 (en) | 2005-02-28 |
| ATE394140T1 (de) | 2008-05-15 |
| WO2003101374A2 (en) | 2003-12-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1106064T1 (el) | Τυποποιηση ενος εστερα τεστοστepονης για ανθρωπινη χρηση | |
| AR117404A2 (es) | Unidad de dosificación que comprende un análogo de prostaglandina para el tratamiento de la constipación | |
| ATE325180T1 (de) | Säureartiges sanitär- und reinigungsmittel enthaltend protonierte carbonsäuren | |
| UY26942A1 (es) | N-acilsulfonamidas promotoras de la apoptosis | |
| AP2003002742A0 (en) | Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids | |
| HRP20030493B1 (hr) | Farmaceutska proizvodnja koja obuhvaća aktivni spoj raspršen po jezgri | |
| CO5680108A1 (es) | Compuestos para el tratamiento de la disfuncion sexual femenina | |
| GB0314624D0 (en) | Inflammatory disease treatment | |
| ECSP055838A (es) | Formulaciones de deposito de liberacion controlada | |
| BR0109925A (pt) | Composição de revestimento para mascaramento de paladar | |
| HN2001000217A (es) | Nuevos tiadiazoles y oxadiazoles y su uso como inhibidores de fosfodiesterasa - 7 | |
| DE60237148D1 (de) | Fettalkohole und fettsäureester zur behandlung von entzündungen | |
| CO5160247A1 (es) | Composicion que cura heridas, antibacteriana bioadhesiva | |
| AR040129A1 (es) | Uso de los esteres de etonogestrel | |
| NZ515016A (en) | HIV protease inhibitor composition | |
| CO5631449A2 (es) | Nuevos esteres de etonogestrel | |
| NZ522242A (en) | Use of 13-hode as a regulator of vascular biocompatibility and an inhibitor of cell hyperplasia | |
| UY26474A1 (es) | Inhibidores de aminotransferasa dependiente de aminoácidos de cadena ramificada, y su uso en el tratamiento de la retinopatía diabética. | |
| AR126166A1 (es) | Combinación de un inhibidor de erk y un inhibidor de kras y usos de estos | |
| NO20006008L (no) | Fettsyreanaloger for behandling av inflammatoriske og autoimmune sykdommer | |
| AR023819A1 (es) | FORMULACIoN FARMACEUTICA, KIT DE PARTES Y UTILIZACION DE DICHA FORMULACION | |
| UY26648A1 (es) | Inhibidores de vasopeptidasa para tratar hipertensión sistólica aislada | |
| BR0005882A (pt) | lcoois de cadeia longa providos em óleos comestìveis | |
| ES2126244T3 (es) | Taco expansible. | |
| DK0942738T3 (da) | Polyetylenglycolestere af polyumættede fedtsyrer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |